Sharemaestro Newsreel

Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27.

Ultragenyx Pharmaceutical is awaiting two crucial FDA decisions that could significantly impact its stock price, potentially raising it from $27 to $32 per share. The decisions involve gene therapy DTX401 for glycogen storage disease type Ia, with an 80% approval chance, and UX111, with …

Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

The FDA has granted RMAT and Fast Track designations to Allogene's TALEN-edited, allogeneic CD19 CAR T-cell therapy, cema-cel, for first-line consolidation in large B-cell lymphoma. An interim analysis showed cema-cel cleared minimal residual disease in a significant proportion of patients, with no serious adverse …

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed

Zenas BioPharma (ZBIO) reported significantly wider losses in Q2 2026, with a net loss of US$111,460,000, despite US$1,000,000 in revenue. These financial results, coupled with leadership changes like the CFO transitioning to a Strategic Advisor role and a new board appointment, are sharpening the …

Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park

Tempest Therapeutics has secured an equity facility of up to $50 million from Lincoln Park Capital Fund, LLC. This agreement provides Tempest with a flexible capital source for operations and clinical development, allowing the company to control the timing and amount of share sales. …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC

Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics (NASDAQ:FULC) by 30% in the second quarter, selling 358,669 shares and retaining 835,204 shares valued at $3.06 million. The company's shares opened at $3.71, near its 12-month low, and it reported a quarterly loss …

Omeros Corporation $OMER Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in Omeros Corporation (NASDAQ:OMER) by 85.2% in the first quarter, now holding 179,594 shares valued at $1.9 million. This comes as Omeros recently reported strong Q2 earnings, beating analyst expectations with $0.02 EPS and $28.53 million …

Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI

Dimensional Fund Advisors LP significantly reduced its stake in OmniAb, Inc. by 18.9% in the first quarter, although it still holds 1.75 million shares valued at $2.74 million. OmniAb exceeded analyst expectations with its recent earnings report, posting a smaller-than-expected loss and higher revenue, …

Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant …

Key facts: MediWound Ltd. (MDWD) Q2 $3.09M rev; EscharEx $4B target

MediWound Ltd. (MDWD) reported Q2 2026 revenue of $3.09–3.10M, with a net loss of $7.39M and shares down 5.4% for the quarter. The company stated that its therapy, EscharEx, is targeting a $4 billion U.S. non-surgical tissue repair market, which it identifies as its …

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Celcuity Inc. announced its Q2 2026 financial results, highlighted by the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA Wild-Type breast cancer and its inclusion in NCCN guidelines. The company plans a commercial launch for REVTORPYK in late Q3 2026 and intends to submit …

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has received an average "Moderate Buy" rating from nineteen brokerages, with an average 12-month price target of $127.81. Recent analyst actions have been mixed, including an upgrade from UBS to "buy" with a $135 target, and price target reductions …

Compugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving Average - Should You Sell?

Compugen (NASDAQ:CGEN) shares recently crossed above their 200-day moving average, closing at $2.41, higher than the $2.28 average. Despite a consensus "Buy" rating and a $5.00 price target from analysts, one analyst downgraded the stock, and Leerink Partners cut its target from $13 to …

CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages

CorMedix Inc (NASDAQ:CRMD) has received an average "Moderate Buy" rating from brokerages, with six out of eight analysts recommending a buy and two recommending a hold. The company's average 12-month price target is $14.86. This follows a strong second quarter where CorMedix beat revenue …

Ultragenyx Stock Looks Undervalued Ahead Of Two FDA Decisions (NASDAQ:RARE)

Ultragenyx Pharmaceutical (RARE) is considered undervalued with a "soft Buy" rating and a probability-weighted fair value of approximately $32 per share, against its current price near $27. The company is anticipating two crucial FDA decisions soon: one for DTX401 on August 23rd and another …

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from seventeen brokerages, with an average 12-month price target of $77.13. The company's stock is currently trading below its recent high, with institutional investors holding a significant 95.45% stake. Recent insider selling has also …

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

Zentalis Pharmaceuticals (ZNTL [https://seekingalpha.com/symbol/ZNTL]) announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20619418-zentalis-pharmaceuticals-announces-pricing-of-underwritten-public-offering] of 23M shares of its common stock at a public offering price of $3.50 per share. Gross proceeds from the offering are expected to be approximately $80.5M before deducting underwriting discounts, …

Outlook Therapeutics Q3 Results: Loss narrows to 8 cents per share

Zentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds …

TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?

TG Therapeutics (TGTX) recently reported its Q2 2026 results, showing higher revenue, lower net income, and raised full-year revenue guidance to about US$950 million. Despite a recent 13% drop, the stock is up 64% year-to-date and is considered modestly undervalued at $47.94 against a …

Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday

Sol-Gel Technologies (SLGL) is expected to announce its Q2 2026 earnings before market open on Friday, August 21st, with analysts projecting a loss of $2.36 per share and revenue of $0.0750 million. This follows a previous quarter where the company reported a smaller loss …

Ladenburg Thalmann Initiates Turn Therapeutics(TTRX.US) With Buy Rating, Announces Target Price $16

Ladenburg Thalmann has initiated coverage on Turn Therapeutics (TTRX.US) with a "Buy" rating. The firm has also set a price target of $16 for the company's stock. This indicates a positive outlook from Ladenburg Thalmann regarding Turn Therapeutics' future performance.

ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and Promising Biomarker Signals in Phase 1b Trial

ProMIS Neurosciences (PMN) reported strong Q2 2026 earnings call highlights, emphasizing zero ARIA-E cases and promising biomarker signals in its Phase 1b PRECISE-AD trial. The company maintains a strong cash position of $53.4 million, funding operations through 2027, and is advancing its pipeline candidates …

Alterity Therapeutics Quotes 354,203 Ordinary Shares Following Option Exercise

Alterity Therapeutics Limited (ASX:ATH) has applied for the quotation of 354,203 new ordinary shares on the ASX, which were issued on August 14, 2026, after the exercise of options under the security code ATHO. These options were exercised at AUD $0.50 per security and …

EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most

Karyopharm Q2 Net Loss Expands; Reaffirms 2026 Revenue Guidance; Plans SNDA For Selinexor In August

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss and provided an update on the company's myelofibrosis program. In addition, the company reaffirmed the full-year 2026 revenue guidance. Karyopharm, …

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday

CNH Industrial (NYSE: CNH) shares surged after reporting better-than-expected Q2 earnings and raising its FY26 adjusted EPS guidance. Several other stocks, including Atkore Inc (NYSE: ATKR), Autolus Therapeutics PLC (NASDAQ: AUTL), and Newell Brands Inc (NASDAQ: NWL), also saw significant gains following positive financial …

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Alpha Cognition Inc. announced its second-quarter 2026 financial results, highlighting a significant 71% quarter-over-quarter increase in ZUNVEYL net product revenue to $6.0 million and a 37% rise in bottles dispensed. The company also reported expanding prescriber base and penetration in long-term care facilities, alongside …

Earnings call transcript: Alpha Cognition posts strong Q2 2026 sales growth

Alpha Cognition (NASDAQ: ACOG) announced strong Q2 2026 results, with ZUNVEYL net product revenue rising 71% sequentially to $6.0 million and total revenue increasing 258% year-over-year. The company narrowed its net loss and cut full-year operating expense guidance, demonstrating commercial momentum for its Alzheimer’s …

Summit Therapeutics (SMMT) Expands Ivonescimab Reach As Investors Ask If The Story Is Priced In

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic P

Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% - Time to Sell?

ATAI Beckley earnings beat by $0.03, revenue topped estimates

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio announced its Q2 2026 financial results and provided a business update, highlighting its progress toward an NDA submission for seralutinib in PAH by September 2026. The company reacquired worldwide development and commercial rights for seralutinib and significantly reduced its debt through a …